Xilio Therapeutics, Inc. (XLO) Q1 2024 Annual Earnings
XLO·Reported May 14, 2024·Before market open
Diluted EPS came in at $-0.62, missed the $-0.11 consensus by $0.51.
Diluted EPS
$-0.62missed by $0.51
Consensus: $-0.11
Financial Snapshot
Trailing eight quarters through Q1 2024
Q1 2024 Earnings FAQ
Common questions about Xilio Therapeutics, Inc.'s Q1 2024 earnings report.
Xilio Therapeutics, Inc. (XLO) reported Q1 2024 earnings on May 14, 2024 before market open.
Xilio Therapeutics, Inc. reported diluted EPS of $-0.62 for Q1 2024.
EPS missed the consensus estimate of $-0.11 by $0.51.
You can read the 10-K periodic report (0001558370-24-004530) directly on SEC EDGAR. The filing index links above go to sec.gov.